Korean biopharma company enters into the next phase with big tech Korean biopharma company Celltrion is known for making the world’s first monoclonal antibody biosimilars, which are used as therapy for rare autoimmune diseases. The Fortune “Future 50" company has since expanded into global markets, forming distribution networks from strategic partnerships. The pharma giant’s global collaboration was accompanied by Microsoft 365 for efficient communication and data sharing. This led to advancing innovation while protecting highly-regulated biopharmaceutical industry data. Customer Celltrion Website: www.celltrion.com Country: South Korea Industry: Pharmaceuticals Customer size: Corporate (2,034 employees) Customer profile Celltrion, Korea's leading bi

Join for free to read